CTS-1027
- CAS No.
- 193022-04-7
- Chemical Name:
- CTS-1027
- Synonyms
- RS130830;CTS-1027;RS-130830;Ro1130830;RS 130830;Ro-1130830;Ro 1130830;RS 130830, Ro-1130830;RS 130830;RO 1130830;CTS1027;CTS 1027;RS130830;RO1130830;RS-130830;RO-1130830;4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide
- CBNumber:
- CB62624116
- Molecular Formula:
- C19H20ClNO6S
- Molecular Weight:
- 425.88
- MDL Number:
- MFCD16657131
- MOL File:
- 193022-04-7.mol
Density | 1.388±0.06 g/cm3(Predicted) |
---|---|
storage temp. | Inert atmosphere,Store in freezer, under -20°C |
solubility | Soluble in DMSO |
form | A solid |
pka | 9.27±0.23(Predicted) |
color | White to off-white |
FDA UNII | 2QD3F58224 |
CTS-1027 price
Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|---|
American Custom Chemicals Corporation | INB0001538 | RS-130830 95.00% | 193022-04-7 | 5MG | $386.1 | 2021-12-16 | Buy |
ChemScene | CS-0281 | CTS-1027 98.45% | 193022-04-7 | 10mg | $396 | 2021-12-16 | Buy |
ApexBio Technology | A3334 | CTS-1027 | 193022-04-7 | 10mg | $483 | 2021-12-16 | Buy |
American Custom Chemicals Corporation | INB0001538 | RS-130830 95.00% | 193022-04-7 | 25MG | $750.75 | 2021-12-16 | Buy |
ChemScene | CS-0281 | CTS-1027 98.45% | 193022-04-7 | 50mg | $1162 | 2021-12-16 | Buy |
CTS-1027 Chemical Properties,Uses,Production
Uses
CTS-1027 is a potent small molecule inhibitor of MMPs, with IC50s of 0.3 nM, 0.5 nM for MMP2, MMP13, respectively, and has > 1,000 fold selectivity over MMP1.
Biological Activity
CTS-1027 is a potent MMP inhibitor with IC50 values of 0.3 nM and 0.5 nM for MMP2 and MMP13, respectively.
in vivo
CTS-1027 significantly reduces the hepatocyte apoptosis, features of cholestatic liver injury, amd markers of hepatic fibrogenesis in the BDL mouse. It improves overall animal survival following 14 days of BDL in mice. In male animals treated for 8 weeks the terminal plasma concentration of RS-130830 is 311±45 nM. Treatment of male mice with RS-130830 for 8 weeks causes an 89% increase in plasma triglyceride concentration, but there is no corresponding effect in female mice treated for 12 Plaque. The lipid content of animals receiving RS-130830 is increased by 81% at 12 weeks, and increased by 41% at 16 weeks.
div>
target
IC50: 0.2 nM (MMP2), 0.5 nM (MMP13), 0.7 nM (MMP12), 0.9 nM (MMP8), 9.5 nM (MMP3), 15 nM (MMP14)
References
[1] Kahraman A, et al. Matrix metalloproteinase inhibitor, CTS-1027, attenuates liver injury and fibrosis in the bile duct-ligated mouse. Hepatol Res. 2009 Aug;39(8):805-813. DOI:10.1111/j.1872-034X.2009.00541.x
[2] Johnson JL, et al. Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. Cardiovasc Res. 2006 Aug 1;71(3):586-595. DOI:10.1016/j.cardiores.2006.05.009
CTS-1027 Preparation Products And Raw materials
Raw materials
Preparation Products
CTS-1027 Suppliers
Supplier | Tel | Country | ProdList | Advantage | |
---|---|---|---|---|---|
ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 33024 | 60 |
career henan chemical co | +86-0371-86658258 +8613203830695 | factory@coreychem.com | China | 29808 | 58 |
TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 | marketing@targetmol.com | United States | 32159 | 58 |
HANGZHOU CLAP TECHNOLOGY CO.,LTD | 86-571-88216897,88216896 13588875226 | sales@hzclap.com | CHINA | 6312 | 58 |
InvivoChem | +1-708-310-1919 +1-13798911105 | sales@invivochem.cn | United States | 6391 | 58 |
TargetMol Chemicals Inc. | support@targetmol.com | United States | 38630 | 58 | |
Shanghai Acmec Biochemical Technology Co., Ltd. | +86-18621343501; +undefined18621343501 | product@acmec-e.com | China | 33338 | 58 |
Aladdin Scientific | tp@aladdinsci.com | United States | 52924 | 58 | |
SHANGHAI KEAN TECHNOLOGY CO., LTD. | +8613817748580 | cooperation@kean-chem.com | China | 40066 | 58 |
Amadis Chemical Company Limited | 571-89925085 | sales@amadischem.com | China | 131957 | 58 |